|
| Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Bullion ~ Forex ~ Sports ~ Technology ~ Health ~ Features |
| Lung Cancer ~ Lung Cancer ~ Breast Cancer ~ Heart attack ~ All Health Topics |
|
Home
/ Health News / 2008 / October 2008 / October 13, 2008 Drug holds promise for reducing coronary artery plaque |
How binge drinking drives heart disease
Lack of exercise put depressed heart patients at greater risk
How cancer prevention drives aging
For the first time, researchers have found how cellular senescence, the well-known mechanism for preventing cancer, can trigger aging and age-related disease by changing the local tissue environment. ANI
Scientists unveil genes vital to vital to adult heart function
In a study on fruit fly Drosophila, scientists at the Burnham Institute for Medical Research (Burnham) have found that genes involved in embryonic heart development are vital to adult heart function in both fruit flies and humans. ANI
Psychiatric disorders common among college-aged
A new study has revealed that psychiatric disorders appear to be common among 18- to 24-year-olds, with overall rates similar among those attending or not attending college. ANI
A commonly used drug for treating high blood pressure, olmesartan, has been found to play an effective role in reducing coronary plaque in a trial.
Washington, Oct 13 : A commonly used drug for treating high blood pressure, olmesartan, has been found to play an effective role in reducing coronary plaque in a trial.
Titled 'Impact of OLmesartan on progression of coronary atherosclerosis', the trial was conducted on 247 angina patients with native coronary artery lesions.
The scientists randomly assigned patients, to receive 20-40mg/day of olmesartan or control.
The participants were then treated with a combination of b-blockers, calcium channel blockers, diuretics, nitrates, glycemic control agents and/or statins per physician's guidance.
Later, Serial Intravenous Ultrasound (IVUS) examinations were performed to assess the amount of coronary plaque before, and 14 months after the start of treatment.
Patient characteristics and all IVUS measurements were identical between the two groups, at the start of the trial. However, after 14 months, IVUS showed significant decreases in measurements of plaque volume in the olmesartan group, despite similar blood pressure readings.
Also, with the help of multivariate analysis, the researchers found that olmesartan administration was one of the factors that caused the decrease in plaque volume.
"Management of plaque is a key front in the war on sudden heart attack. These results suggest a positive role in potential plaque regression through the administration of olmesartan, an angiotension-II receptor blocking agent, for patients with stable angina pectoris," said Dr. Atsushi Hirohata, Cardiovascular Medicine, the Sakakibara Heart Institute of Okayama, Okayama, Japan and lead author of the study.
The study was presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).
ANI
